Hikma Pharmaceuticals PLC (LON:HIK) Stock Has Average Target Price of GBX 2,085.83

Key Points

• Analyst sentiment is uniformly positive: All six analysts covering Hikma Pharmaceuticals rate the stock “Buy,” with an average 12-month price target of GBX 2,085.83 versus a recent price of GBX 1,599.
• Several firms recently raised their targets, including Berenberg to GBX 2,100 and Citigroup to GBX 1,870; Deutsche Bank and Jefferies maintained “Buy” ratings.
• Insider confidence increased: Director Tobias Hestler purchased 7,500 shares for £123,600, while insiders collectively own 22.26% of the company.

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have been given an average recommendation of "Buy" by the six research firms that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is GBX 2,085.83.

A number of research firms have recently commented on HIK. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Berenberg Bank raised their price objective on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Citigroup lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a research note on Friday.

Insider Activity at Hikma Pharmaceuticals

In other news, insider Tobias Hestler acquired 7,500 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.26% of the company's stock.

Hikma Pharmaceuticals Stock Up 0.4%

Shares of LON:HIK opened at GBX 1,599 on Tuesday. The company has a market capitalization of £3.31 billion, a PE ratio of 9.09, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27. The business has a fifty day moving average price of GBX 1,603.76 and a two-hundred day moving average price of GBX 1,480.98. Hikma Pharmaceuticals has a 1 year low of GBX 1,187 and a 1 year high of GBX 1,865.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.